drugset
drugset / Trial / NCT03054909

IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

NCT03054909 ↗

Phase 2 Completed 7 enrolled Masonic Cancer Center, University of Minnesota
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single center, randomized phase II study of an IL-15Rα-Fc super-agonist complex (ALT-803) given as maintenance therapy after the completion of 1st line IV/IP chemotherapy for the treatment of advanced ovarian, fallopian tube, and primary peritoneal cancer.

Timeline

Start
2017-09-19
Primary completion
2022-02-16
Completion
2022-02-16

Drugs

EvaluationDrugModalityDoseRoute
Subject N-803 Protein / enzyme biologic 10 ug/kg Subcutaneous

Indications

fallopian tube cancer primary peritoneal carcinoma uterine adnexa cancer